These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26673349)

  • 21. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in strategies and methodologies in cancer immunotherapy.
    Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
    Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Engineering Cells for Cancer Immunotherapy.
    Xu X; Li T; Shen S; Wang J; Abdou P; Gu Z; Mo R
    Theranostics; 2019; 9(25):7889-7905. PubMed ID: 31695806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Breast Cancer- Paving New Roads?
    Truica CI; Cleary AS
    Curr Mol Pharmacol; 2016; 9(3):208-216. PubMed ID: 26177646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
    Shapira S; Lisiansky V; Arber N; Kraus S
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lymphomas: A therapeutic update].
    Wolfromm A; Delarue R
    Rev Med Interne; 2017 Oct; 38(10):685-690. PubMed ID: 28958786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F; Del Vecchio M; Castagnoli L; De Braud F; Di Cosimo S; Franceschini D; Fucà G; Hiscott J; Malmberg KJ; McGranahan N; Pietrantonio F; Rivoltini L; Sangaletti S; Tagliabue E; Tripodo C; Vernieri C; Zitvogel L; Pupa SM; Di Nicola M
    Cytokine Growth Factor Rev; 2018 Dec; 44():1-10. PubMed ID: 30393044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents.
    Abu-Shawer O; Bushnaq T; Abu-Shawer M
    Gulf J Oncolog; 2019 Jan; 1(29):76-82. PubMed ID: 30956199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer immune therapy for lymphoid malignancies: recent advances.
    Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
    Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.